SIRT1 — research review 2

...and this is where we see the rubber meet the road between exciting lab science and what clinical trials actually show us, particularly for longevity.

Exactly. We often hear about molecules like SIRT1, an NAD⁺-dependent longevity deacetylase, and how it's activated by things like resveratrol. It sounds incredibly promising, and in petri dishes or mice, the effects on autophagy, for example, are clear.

Right. SIRT1 uses NAD⁺ as fuel; without enough NAD⁺, this key enzyme simply can't do its job, which includes promoting autophagy by deacetylating relevant proteins. Resveratrol is a classic SIRT1 activator, partly mimicking caloric restriction. Pterostilbene, a methylated resveratrol analog, also activates SIRT1 and has better bioavailability.

But when we move to human trials, especially for direct longevity outcomes, the picture becomes a lot less clear. Take a look at a review like the one in Aging Cell from 2020. While we see some promising biomarkers in certain studies, direct evidence of these compounds extending human lifespan or significantly delaying age-related diseases is largely still unproven.

Absolutely. Many initial human studies are small, short-term, and focused on surrogate markers, not actual lifespan or healthspan improvement. We have tantalizing hints, but null results, or studies showing no significant effect, are also out there and equally important to consider.

So, while the underlying biology of SIRT1 and its activators remains a fascinating area of research, the jump to human application for longevity is still very much in progress, with much left unknown about long-term efficacy and safety.